Quantitative analysis of contrast enhanced spectral mammography grey value for early prediction of pathological response of breast cancer to neoadjuvant chemotherapy
Authors:
Open Access
- 15 March 2021
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 11 (1) , 1-9
Abstract
A quantitative analysis of contrast-enhanced spectral mammography (CESM) enhancement was conducted for the early prediction of the pathological response after neoadjuvant chemotherapy (NAC). Retrospective analysis of the data of 111 patients was conducted, and all of them underwent NAC in our hospital and surgical resection after the end of all cycles from January 2018 to May 2019. They were divided into pathological complete response (PCR) and non-PCR groups. We determined whether a statistical difference in the percentage of CESM grey value reduction (ΔCGV) was present in the PCR and non-PCR groups and whether a statistical difference was observed in the diagnostic efficiency of craniocaudal (CC) and mediolateral oblique (MLO) view subtraction images. Independent sample t-test was used to compare different groups, the receiver operating characteristic (ROC) curve was used to compare the diagnostic efficacy of CC and MLO for pathological response after NAC, and the Delong test was used to compare the area under the ROC curve (AUC). Statistical significance was considered at P < 0.05. A statistical difference was observed in the ΔCGV in the PCR and non-PCR groups. No statistical difference was observed in the AUCs of CC and MLO view subtraction images. The ΔCGV can be used as a quantitative index to predict PCR early, and no statistical difference was observed in the diagnostic efficacy of CC and MLO view subtraction images.Keywords
This publication has 33 references indexed in Scilit:
- Magnetic resonance imaging in breast cancer management in the context of neo-adjuvant chemotherapyCritical Reviews in Oncology/Hematology, 2018
- Contrast-Enhanced Spectral Mammography is Comparable to MRI in the Assessment of Residual Breast Cancer Following Neoadjuvant Systemic TherapyAnnals of Surgical Oncology, 2018
- Contrast-enhanced spectral mammography (CESM) versus breast magnetic resonance imaging (MRI): A retrospective comparison in 66 breast lesionsDiagnostic and Interventional Imaging, 2017
- Magnetic resonance imaging evaluation of residual tumors in breast cancer after neoadjuvant chemotherapy: surgical implicationsActa Radiologica, 2015
- Evaluation of low-energy contrast-enhanced spectral mammography images by comparing them to full-field digital mammography using EUREF image quality criteriaEuropean Radiology, 2015
- Meta-analysis confirms achieving pathological complete response after neoadjuvant chemotherapy predicts favourable prognosis for breast cancer patientsEuropean Journal of Cancer, 2011
- Neoadjuvant Chemotherapy of Breast Cancer: Tumor Markers as Predictors of Pathologic Response, Recurrence, and SurvivalThe Breast Journal, 2010
- Preoperative Therapy in Invasive Breast Cancer: Pathologic Assessment and Systemic Therapy Issues in Operable DiseaseJournal of Clinical Oncology, 2008
- Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006Annals of Oncology, 2007
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant ChemotherapyJournal of Clinical Oncology, 1999